Cargando…
The efficacy and safety of pulmonary vasodilators in patients with Fontan circulation: a meta-analysis of randomized controlled trials
No previous meta-analysis has evaluated the efficacy and safety of pulmonary vasodilators in Fontan physiology. Recent relative trials have obtained conflicting results regarding improvements in peak oxygen consumption; the relatively small number of patients in each study may be a limiting factor....
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348526/ https://www.ncbi.nlm.nih.gov/pubmed/29972332 http://dx.doi.org/10.1177/2045894018790450 |
_version_ | 1783390116391157760 |
---|---|
author | Wang, Wuwan Hu, Xiankang Liao, Weitin Rutahoile, W.H. Malenka, David J. Zeng, Xiaofang Yang, Yunjing Feng, Panpan Wen, Li Huang, Wei |
author_facet | Wang, Wuwan Hu, Xiankang Liao, Weitin Rutahoile, W.H. Malenka, David J. Zeng, Xiaofang Yang, Yunjing Feng, Panpan Wen, Li Huang, Wei |
author_sort | Wang, Wuwan |
collection | PubMed |
description | No previous meta-analysis has evaluated the efficacy and safety of pulmonary vasodilators in Fontan physiology. Recent relative trials have obtained conflicting results regarding improvements in peak oxygen consumption; the relatively small number of patients in each study may be a limiting factor. We aimed to evaluate the efficacy and safety of pulmonary vasodilators in Fontan patients. Relevant studies were identified by searching the PubMed, Embase, and Cochrane Library databases. Pooled outcomes were determined to assess the efficacy and safety of pulmonary vasodilators in Fontan patients. Nine randomized controlled studies involving 381 patients with Fontan circulation were included. Pulmonary vasodilator therapy led to significant improvement (mean difference = −0.39, 95% CI: [−0.72, −0.05]) in the New York Heart Association (NYHA) functional class. The 6-minute walking distance (6MWD) was significantly increased by 134 m (95% CI: [86.07, 181.94]), and the peak VO(2) was also significantly improved (mean difference = 1.42 ml·(kg·min)(-1), 95% CI: [0.21, 2.63]). Additionally, the mean pulmonary artery pressure (mPAP) was significantly reduced (mean difference = −2.25 mmHg, 95% CI: [−3.00, −1.50]). No significant change was found in mortality or in brain natriuretic peptide (BNP) or N-terminal pronatriuretic peptide (NT-proBNP). Four studies reported no side effects and good drug tolerance, and two studies reported mild adverse effects. The present meta-analysis indicated that pulmonary vasodilators (primarily the PDE-5 inhibitor and endothelin-1 receptor antagonist) significantly improved the hemodynamics of Fontan patients, reduced the NYHA functional class and increased the 6MWD. The peak oxygen consumption was also improved. No significant change was observed in mortality or in the BNP or NT-proBNP level. Overall, the pulmonary vasodilators were well tolerated. This finding needs to be confirmed in future studies. |
format | Online Article Text |
id | pubmed-6348526 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-63485262019-02-04 The efficacy and safety of pulmonary vasodilators in patients with Fontan circulation: a meta-analysis of randomized controlled trials Wang, Wuwan Hu, Xiankang Liao, Weitin Rutahoile, W.H. Malenka, David J. Zeng, Xiaofang Yang, Yunjing Feng, Panpan Wen, Li Huang, Wei Pulm Circ Research Article No previous meta-analysis has evaluated the efficacy and safety of pulmonary vasodilators in Fontan physiology. Recent relative trials have obtained conflicting results regarding improvements in peak oxygen consumption; the relatively small number of patients in each study may be a limiting factor. We aimed to evaluate the efficacy and safety of pulmonary vasodilators in Fontan patients. Relevant studies were identified by searching the PubMed, Embase, and Cochrane Library databases. Pooled outcomes were determined to assess the efficacy and safety of pulmonary vasodilators in Fontan patients. Nine randomized controlled studies involving 381 patients with Fontan circulation were included. Pulmonary vasodilator therapy led to significant improvement (mean difference = −0.39, 95% CI: [−0.72, −0.05]) in the New York Heart Association (NYHA) functional class. The 6-minute walking distance (6MWD) was significantly increased by 134 m (95% CI: [86.07, 181.94]), and the peak VO(2) was also significantly improved (mean difference = 1.42 ml·(kg·min)(-1), 95% CI: [0.21, 2.63]). Additionally, the mean pulmonary artery pressure (mPAP) was significantly reduced (mean difference = −2.25 mmHg, 95% CI: [−3.00, −1.50]). No significant change was found in mortality or in brain natriuretic peptide (BNP) or N-terminal pronatriuretic peptide (NT-proBNP). Four studies reported no side effects and good drug tolerance, and two studies reported mild adverse effects. The present meta-analysis indicated that pulmonary vasodilators (primarily the PDE-5 inhibitor and endothelin-1 receptor antagonist) significantly improved the hemodynamics of Fontan patients, reduced the NYHA functional class and increased the 6MWD. The peak oxygen consumption was also improved. No significant change was observed in mortality or in the BNP or NT-proBNP level. Overall, the pulmonary vasodilators were well tolerated. This finding needs to be confirmed in future studies. SAGE Publications 2019-01-14 /pmc/articles/PMC6348526/ /pubmed/29972332 http://dx.doi.org/10.1177/2045894018790450 Text en © The Author(s) 2019 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Research Article Wang, Wuwan Hu, Xiankang Liao, Weitin Rutahoile, W.H. Malenka, David J. Zeng, Xiaofang Yang, Yunjing Feng, Panpan Wen, Li Huang, Wei The efficacy and safety of pulmonary vasodilators in patients with Fontan circulation: a meta-analysis of randomized controlled trials |
title | The efficacy and safety of pulmonary vasodilators in patients with Fontan circulation: a meta-analysis of randomized controlled trials |
title_full | The efficacy and safety of pulmonary vasodilators in patients with Fontan circulation: a meta-analysis of randomized controlled trials |
title_fullStr | The efficacy and safety of pulmonary vasodilators in patients with Fontan circulation: a meta-analysis of randomized controlled trials |
title_full_unstemmed | The efficacy and safety of pulmonary vasodilators in patients with Fontan circulation: a meta-analysis of randomized controlled trials |
title_short | The efficacy and safety of pulmonary vasodilators in patients with Fontan circulation: a meta-analysis of randomized controlled trials |
title_sort | efficacy and safety of pulmonary vasodilators in patients with fontan circulation: a meta-analysis of randomized controlled trials |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348526/ https://www.ncbi.nlm.nih.gov/pubmed/29972332 http://dx.doi.org/10.1177/2045894018790450 |
work_keys_str_mv | AT wangwuwan theefficacyandsafetyofpulmonaryvasodilatorsinpatientswithfontancirculationametaanalysisofrandomizedcontrolledtrials AT huxiankang theefficacyandsafetyofpulmonaryvasodilatorsinpatientswithfontancirculationametaanalysisofrandomizedcontrolledtrials AT liaoweitin theefficacyandsafetyofpulmonaryvasodilatorsinpatientswithfontancirculationametaanalysisofrandomizedcontrolledtrials AT rutahoilewh theefficacyandsafetyofpulmonaryvasodilatorsinpatientswithfontancirculationametaanalysisofrandomizedcontrolledtrials AT malenkadavidj theefficacyandsafetyofpulmonaryvasodilatorsinpatientswithfontancirculationametaanalysisofrandomizedcontrolledtrials AT zengxiaofang theefficacyandsafetyofpulmonaryvasodilatorsinpatientswithfontancirculationametaanalysisofrandomizedcontrolledtrials AT yangyunjing theefficacyandsafetyofpulmonaryvasodilatorsinpatientswithfontancirculationametaanalysisofrandomizedcontrolledtrials AT fengpanpan theefficacyandsafetyofpulmonaryvasodilatorsinpatientswithfontancirculationametaanalysisofrandomizedcontrolledtrials AT wenli theefficacyandsafetyofpulmonaryvasodilatorsinpatientswithfontancirculationametaanalysisofrandomizedcontrolledtrials AT huangwei theefficacyandsafetyofpulmonaryvasodilatorsinpatientswithfontancirculationametaanalysisofrandomizedcontrolledtrials AT wangwuwan efficacyandsafetyofpulmonaryvasodilatorsinpatientswithfontancirculationametaanalysisofrandomizedcontrolledtrials AT huxiankang efficacyandsafetyofpulmonaryvasodilatorsinpatientswithfontancirculationametaanalysisofrandomizedcontrolledtrials AT liaoweitin efficacyandsafetyofpulmonaryvasodilatorsinpatientswithfontancirculationametaanalysisofrandomizedcontrolledtrials AT rutahoilewh efficacyandsafetyofpulmonaryvasodilatorsinpatientswithfontancirculationametaanalysisofrandomizedcontrolledtrials AT malenkadavidj efficacyandsafetyofpulmonaryvasodilatorsinpatientswithfontancirculationametaanalysisofrandomizedcontrolledtrials AT zengxiaofang efficacyandsafetyofpulmonaryvasodilatorsinpatientswithfontancirculationametaanalysisofrandomizedcontrolledtrials AT yangyunjing efficacyandsafetyofpulmonaryvasodilatorsinpatientswithfontancirculationametaanalysisofrandomizedcontrolledtrials AT fengpanpan efficacyandsafetyofpulmonaryvasodilatorsinpatientswithfontancirculationametaanalysisofrandomizedcontrolledtrials AT wenli efficacyandsafetyofpulmonaryvasodilatorsinpatientswithfontancirculationametaanalysisofrandomizedcontrolledtrials AT huangwei efficacyandsafetyofpulmonaryvasodilatorsinpatientswithfontancirculationametaanalysisofrandomizedcontrolledtrials |